Orchestra BioMed Holdings (OBIO) Cash from Financing Activities (2022 - 2026)

Orchestra BioMed Holdings (OBIO) has 5 years of Cash from Financing Activities data on file, last reported at $5.5 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 1967.23% year-over-year to $5.5 million in Q1 2026; TTM through Mar 2026 was $94.2 million, a 226.28% increase from a year earlier, with the FY2025 full-year figure at $88.3 million, up 202.81% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $5.5 million, down from $12.7 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for OBIO reached as high as $86.1 million in Q2 2022 and fell as low as -$10.7 million in Q4 2023.
• Historically, Cash from Financing Activities has averaged $16.0 million across 5 years, with a median of $171000.0 in 2024.
• Across the five-year window, Cash from Financing Activities jumped 375775.0% in 2024 and slumped 1744.44% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at -$5.1 million in 2022, then tumbled by 110.14% to -$10.7 million in 2023, then jumped by 230.39% to $13.9 million in 2024, then decreased by 9.23% to $12.7 million in 2025, then sank by 56.34% to $5.5 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $5.5 million in Q1 2026, $12.7 million in Q4 2025, and $76.4 million in Q3 2025.